Want to join the conversation?
Drug and medical device maker $BAX reported a jump in 2Q16 earnings driven by a $1.1Bil realized gains on the disposition of its retained shares in Baxalta. Net income rose to $1.21Bil or $2.19 per share from $332MM or $0.60 per share last year. Net sales grew to $2.59Bil from $2.48Bil. Adjusted EPS increased to $0.46 from $0.19.
Any idea why some investors are happy about the disastrous $UA results??
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.